Intraoperative Avidination for Radionuclide Therapy: A Prospective New Development to Accelerate Radiotherapy in Breast Cancer
暂无分享,去创建一个
A. Luini | U. Veronesi | L. Travaini | M. Ferrari | R. De Santis | M. Cremonesi | L. Ravasi | G. Paganelli | V. Galimberti | C. De Cicco | P. Carminati | M. Chinol | M. Fiorenza | G. Sivolapenko | S. Papi | C. Zanna
[1] Giampiero Tosi,et al. Dosimetry in Peptide radionuclide receptor therapy: a review. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] J. Chatal,et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Luini,et al. Conservative Treatment of Breast Cancer: Its Evolution , 2005, Breast Cancer Research and Treatment.
[4] Roberto Orecchia,et al. Full-Dose Intraoperative Radiotherapy With Electrons During Breast-Conserving Surgery: Experience With 590 Cases , 2005, Annals of surgery.
[5] Michael G Stabin,et al. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] M. Baum,et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. , 2005, Seminars in radiation oncology.
[7] R. Dale,et al. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. , 2005, Cancer biotherapy & radiopharmaceuticals.
[8] S. Formenti,et al. Biologic comparison of partial breast irradiation protocols. , 2004, International journal of radiation oncology, biology, physics.
[9] R. Dale,et al. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. , 2004, Cancer biotherapy & radiopharmaceuticals.
[10] P. Erba,et al. Clinical feasibility of two-step streptavidin/111In-biotin scintigraphy in patients with suspected vertebral osteomyelitis , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[11] F. Vicini,et al. Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. , 2003, International journal of radiation oncology, biology, physics.
[12] O. de Cobelli,et al. Localization of avidin in superficial bladder cancer: a potentially new approach for radionuclide therapy. , 2003, European urology.
[13] M. Konijnenberg,et al. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients? , 2003, Cancer biotherapy & radiopharmaceuticals.
[14] W. McBride,et al. Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[15] Umberto Veronesi,et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. , 2002, The New England journal of medicine.
[16] G. Németh,et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: Five‐year results of a phase I–II study and initial findings of a randomized phase III trial , 2002, Journal of surgical oncology.
[17] P. Caliceti,et al. Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study , 2002, British Journal of Cancer.
[18] P. Caliceti,et al. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. , 2001, Cancer biotherapy & radiopharmaceuticals.
[19] Robert C. Frazier,et al. Accelerated treatment of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] P. Beaumier,et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[21] W. F. Athas,et al. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. , 2000, Journal of the National Cancer Institute.
[22] M. Goris,et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] M. Ferrari,et al. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients , 1999, European Journal of Nuclear Medicine.
[24] B. Wessels,et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] H. Sakahara,et al. Avidin targeting of intraperitoneal tumor xenografts. , 1998, Journal of the National Cancer Institute.
[26] F. Fazio,et al. Imaging osteomyelitis with streptavidin and indium-111-labeled biotin. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] R G Dale,et al. Dose-rate effects in targeted radiotherapy. , 1996, Physics in medicine and biology.
[28] P. Schubiger,et al. Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. , 1996, Bioconjugate chemistry.
[29] G Sgouros,et al. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] M. Stabin,et al. MIRD Pamphlet No. 14: a dynamic urinary bladder model for radiation dose calculations. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] M. Goitein,et al. Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.
[32] M. Ginanneschi,et al. Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT®) , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[33] Marion de Jong,et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] S. Adelstein,et al. Radiobiologic principles in radionuclide therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] Raffaella Barone,et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[36] D M Foster,et al. Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. , 1998, Advances in experimental medicine and biology.
[37] F. Fazio,et al. Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.